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Human leukocyte antigen-G (HLA-G) is a low polymorphic nonclassical HLA-I molecule restrictively expressed and with
suppressive functions. HLA-G gene products are quite complex, with seven HLA-G isoforms, four membrane bound, and other
three soluble isoforms that can suffer different posttranslational modifications or even complex formations. In addition, HLA-G has
been described included in exosomes. In this reviewwewill focus onHLA-Gbiochemistrywith special emphasis to themechanisms
that regulate its expression and how the protein modifications affect the quantification in biological fluids.
1. Introduction
Human leukocyte antigen-G (HLA-G) is a major histo-
compatibility complex class I antigen encoded by a gene
on chromosome 6p21. It differs from classical HLA class
I molecules by its restricted tissue distribution and lim-
ited polymorphism in the coding region. HLA-G role in
immune tolerance was uncovered studying its expression
in trophoblast cells at fetus-maternal interface [1]. Several
studies have found an aberrant or reduced expression of
both HLA-G mRNA and protein in pathological condi-
tions such as preeclampsia [2] or recurrent spontaneous
abortion [3] in comparison with normal placentas. HLA-
G expression has been documented in few tissues during
physiological conditions, such as cornea, thymus, erythroid,
and endothelial precursors [4–6], and in a variable percentage
of serum/plasma samples from healthy subjects [7] where
the main producers seem to be activated CD14+ monocytes
[8]. An ectopic expression of HLA-G molecules has been
observed during “no-physiological” conditions, such as viral
infection [9–12], cancer [13], transplantation [14–18], and
in inflammatory and autoimmune diseases [19–21]. Thus, a
growing body of evidence has indicated HLA-G as a suitable
key actor in different pathologies. In fact, HLA-Gmay exhibit
two distinct effects in pathological conditions: it could be
protective in inflammatory and autoimmune diseases [22] or
it could be dangerous, for example, in tumors or infectious
diseases.
2. HLA-G Expression and Regulation
The HLA-G production is controlled by several polymor-
phisms both in the promoter and in the 3󸀠 untranslated region
(3󸀠 UTR) that modify the affinity of gene targeted sequences
for transcriptional or posttranscriptional factors, respectively
[24]. Twenty-nine single nucleotide polymorphisms (SNPs)
have been identified in the HLA-G promoter region, which
may be involved in the regulation of HLA-G expression,
considering that many of these polymorphisms are within
or close to known or putative regulatory elements (Figure 1).
The HLA-G 5󸀠 upstream regulatory region (URR) is unique
among theHLA genes [25] and is unresponsive toNF-𝜅B [25]
and IFN-𝛾 [26], due to the presence of amodified enhancer A
(enhA) and a deleted interferon-stimulated response element
(ISRE). A locus control region (LCR) located −1.2 kb from
exon 1 exhibits a binding site for CREB1 factor, which also
binds to two additional cAMP response elements at −934
and −770 positions from the ATG start codon. In addition,
an ISRE for IFN response factor-1 (IRF-1) is located at
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Figure 1: HLA-G unique promoter region. Enhancer A element (ΚB1, ΚB2, Sp1): NF-ΚB; interferon-stimulated regulatory element (ISRE);
interferon regulatory factor (IRF); interferon-gamma activated site (GAS); SXY region; progesterone response element (PRE); hypoxia
response element (HRE).
the−744 bp position [24] and is involved inHLA-G transacti-
vation following IFN-𝛽 treatment [27].TheHLA-G promoter
also contains a heat shock element at the −459/−454 position
that binds heat shock factor-1 (HSF-1) [28] and a progesterone
receptor binding site at −37 bp from ATG start codon [29].
Several promoter region polymorphisms coincide with or
are close to known or putative regulatory elements and thus
may affect the binding of HLA-G regulatory factors [30].
The −725C>G/T SNP is very close to ISRE, and the −725G
allele is associated with a significantly higher expression level
compared with the other alleles [31]. The polymorphic sites
at the 5󸀠 URR are frequently in linkage disequilibrium (LD)
with the polymorphic sites identified at the 3󸀠 UTR, some
of them influencing alternative splicing and mRNA stability
[25].
A 14 base pair (14 bp) insertion/deletion (INS/DEL) poly-
morphism (rs66554220) in exon 8 involves mRNA stability
and expression [32]. In particular, theDEL allele stabilizes the
mRNAwith a consequent higher HLA-G expression [33, 34].
The presence of an adenine at position +3187, modifying an
AU-rich motif in the HLA-G mRNA, decreases its stability
[35]. One single nucleotide polymorphism (SNP) C>G at
the +3142 bp position (rs1063320) has been explored by Tan
and coauthors [36]. The presence of a guanine at the +3142
position may influence the expression of the HLA-G locus by
increasing the affinity of this region for the microRNAs miR-
148a,miR-148b, andmiR-152, therefore decreasing themRNA
availability for translation bymRNAdegradation and transla-
tion suppression. The influence of the +3142G allele has been
demonstrated by a functional study in which HLA-G high-
expressing JEG-3 choriocarcinoma-derived cells have been
transfected with miR-148a, decreasing soluble HLA-G levels.
The contrasting results obtained by Manaster and coauthors
[37], who have reported the absence of +3142C>G effect on
themiRNA control of membraneHLA-G expression, prompt
further considerations on the relationship between this poly-
morphism and membrane HLA-G expression. Other SNPs
have been identified as implicated in miRNA interaction. In
particular, +3003, +3010, +3027, and +3035 SNPs are influ-
enced by miR-513a-5p, miR-518c∗, miR-1262 and miR-92a-
1∗, miR-92a-2∗, miR-661, miR-1224-5p, and miR-433 miR-
NAs [35]. The miR-2110, miR-93, miR-508-5p, miR-331-5p,
miR-616, miR-513b, and miR-589∗ miRNAs target the 14 bp
INS/DEL fragment region, and miR-148a, miR-19a∗, miR-
152, mir-148b, and miR-218-2 also influence the +3142C/G
polymorphism.
HLA-G is a stress-inducible gene: heat shock, hypoxia,
and arsenite increase different HLA-G alternative transcripts
[28, 38]. The indolamine 2,3-dioxygenase (IDO), an enzyme
which metabolizes tryptophan, induces HLA-G expression
during monocyte differentiation into dendritic cells [39].
Interestingly, HLA-G exerts its immune tolerogenic function
towards T cell alloproliferation following an independent
pathway from IDO [40]. Nitric oxide-dependent nitration
of both cellular and soluble HLA-G protein decreases total
HLA-G cellular protein content and expression on the
cell surface, while it increases HLA-G shedding into the
culture medium. This effect was posttranscriptional and
the result of metalloprotease activity [41–43]. Several evi-
dences indicate that the soluble HLA-G1 (sHLA-G1) form
is generated through the shedding of the membrane bound
HLA-G1 by metalloproteinase (MP) [44–47]. In particular,
matrix metalloproteinase-2 (MMP-2), a zinc-containing and
calcium-requiring endopeptidase known for the ability to
cleave several extracellular matrix constituents, as well as
nonmatrix proteins, is responsible for HLA-G1 membrane-
shedding via three possible highly specific cleavage sites [48].
The anti-inflammatory and immunosuppressive
interleukin- (IL-) 10 has been correlated with concomitant
HLA-G expression [33]. Transactivation of HLA-G trans-
cription has also been demonstrated by leukemia inhibitory
factor (LIF) [49] and methotrexate cell exposure [50].
Furthermore, interferon (IFN)-𝛼, -𝛽, and -𝛾 enhance HLA-G
cell-surface expression by tumors or monocytes [51, 52].
HLA-G expression could be acquired by trogocytosis,
where a “donor” cell that expresses membrane HLA-G
exchanges membrane parts containing HLA-G with a
“recipient” cell that is not expressing HLA-G molecules. In
this particular situation, “recipient” cells will acquire and
make use of membrane HLA-G molecules from a “donor”
HLA-G positive cell without the activation of HLA-G gene
transduction into protein. Trogocytosis of HLA-G from
antigen presenting cell (APC) by T cells in humans makes
these T cells unresponsive [53]. It has been shown that NK
cells can acquire HLA-G1 from tumor cells, which provokes
an arrest of NK cells proliferation and cytotoxic activity,
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behaving like suppressor cells capable of inhibiting other NK
cell functions [54].
3. HLA-G Transcription Products
To date, 50 alleles (IMGTHLAdatabase, December 2013) and
16 proteins are known. Seven HLA-G isoforms exist due to
mRNA alternative splicing and differential association with
𝛽2-microglobulin (𝛽2-m). Four of them are found on the cell
surface (HLA-G1, -G2, -G3, and -G4), while the other three
are soluble forms released from the cell (HLA-G5, -G6, and
-G7), due to the lack of the transmembrane and intracellular
domains of membrane-bound HLA-G (Figure 2). The HLA-
G 14 bp INS/DEL polymorphism is involved in the expression
of both HLA-G1 and HLA-G5 isoforms, with decreased
HLA-G1 and HLA-G5 concentrations in 14 bp INS samples
in comparison with 14 bp DEL samples [32, 34].
The overall structure of HLA-G resembles other class I
MHC molecules, in which a heavy chain comprised of three
extracellular domains is noncovalently associated with 𝛽2-
m (Figure 2). A nine-residue self-peptide is bound within
a cleft formed by two alpha-helices and a beta-sheet floor.
An extensive network of contacts is formed between the
peptide and the binding cleft, leading to a constrained mode
of binding reminiscent of that observed in HLA-E [65].
4. HLA-G Receptors
HLA-G exerts its immunomodulatory functions through
the interaction with multiple receptors such as LILRB1
(ILT2/CD85j), LILRB2 (ILT4/CD85d), and KIR2DL4
(CD158d), which are differentially expressed by immune
cells. The interaction of HLA-G molecules with inhibitory
receptors induces apoptosis of activated CD8+ T cells [66],
modulates the activity of NK cells [67] and dendritic
cells (DC) [68], blocks allocytotoxic T lymphocyte
response, induces expansion of T cell populations such
as CD4+CD25+FoxP3+ regulatory T (Treg) cells [69]
and CD3+CD4lowFoxp3− and CD3+CD8lowFoxp3− [70], and
inhibits V𝛾9V𝛿2 T-cell proliferation and cytotoxicity without
inducing apoptosis [71]. Moreover, HLA-G is expressed at
high levels on DC-10 cells, human DCs with tolerogenic
activity and an outstanding ability to produce IL-10 [72].
Interestingly, the expression of membrane-bound HLA-G1
and its receptors is upregulated by IL-10 on DC-10 and the
expression of high levels of membrane-bound HLA-G1,
ILT4, and IL-10 by DC-10 is critical to the generation of
allergen-specific Tr1 cells by DC-10.
Whereas LILRB1 is expressed by NK cells, T cells, DCs,
and decidual macrophages, LILRB2 expression is restricted
to monocytes, macrophages, and DCs. These receptors can
bind both classical andnonclassicalHLA-Imolecules [73, 74].
However, they present more affinity for HLA-G than for
classicalHLA-Imolecules [75]. Also,HLA-G interactionwith
LILRB1 on NK cells and the resultant inhibitory function do
not require tumor cell lipid raft integrity [76]. This differs
from classical HLA-I, which are recruited in lipid rafts upon
receptor engagement [77].
LILRB1 and LILRB2 possess 4 extracellular domains (D1–
D4) and four and three immunoreceptor tyrosine-based
inhibitory motifs (ITIMs), respectively, in their long cyto-
plasmic tails. These ITIM motifs confer them inhibitory
characteristics, contrary to other LILR family receptors with
activating properties that lack these ITIM motifs and pos-
sess an Arg residue in the transmembrane domain [74].
Interaction of LILRB1 and LILRB2 with their ligands causes
phosphorylation of these ITIMS and recruitment of SHP
phosphatases that initiate the inhibitory cascade. The D1 and
D2 domains mediate the interaction of these receptors with
HLA-I molecules and in the case of LILRB1 that occurs with
the 𝛼3-domain and 𝛽2-m [74]. In fact, 𝛽2-m free HLA-G
molecules are not recognized by LILRB1 [78]. However, in the
case of LILRB2, it seems that interactions of these receptors
with HLA-I molecules implicate the conservative residues of
𝛼3-domain but not of 𝛽2-m [73, 74]. HLA-G can form dimers
that bind to LILR receptors with even a higher affinity than
HLA-G monomers [79], being able to bind two receptors
simultaneously [80].
Another HLA-G receptor is KIR2DL4 or CD158d, the
only receptor of the killer cell immunoglobulin-like receptors
(KIR) family that is expressed in all NK cell types [67].
KIR family includes receptors with activating properties and
receptors with inhibitory properties. KIR2DL4 has unique
structural properties among the rest of KIR receptors: it
possesses a long cytoplasmic tail characteristic of inhibitory
receptors, a charged amino acid in the transmembrane
domain similarly to activating KIR receptors (reviewed [81]),
and a mixed structure in the extracellular part with D0 and
D2 domains. Contrary to other KIR receptors, KIR2DL4
expression is transitory on NK cell surface, with a main
expression in endosomes, reached by an endocytic process.
KIR2DL4 seems to participate toHLA-G endocytosis when it
is transient expressed on NK cell surface, as both HLA-G and
KIR2DL4 can be simultaneously colocalized in endosomes
[82].This could explainwhy solubleHLA-Gor anti-KIR2DL4
antibodies, but not solid-phase bound antibodies, can induce
cytokine secretion by NK resting cells. However, KIR2DL4
expression can be induced by IL-2 and its activation upon
antibodies engagement provokes a weak cytotoxic activity
with a strong IFN-𝛾 production [83].
In vitro studies have shown that KIR2DL4 is able to
interact with 𝛽2-m free HLA-G molecules, inducing IFN-
𝛾 production [84] and increasing NK cell cytotoxicity [19].
Contrary to LILR receptors, KIR does not bind HLA-I
molecules through its 𝛼3 domain but through 𝛼1 and 𝛼2
domains which are muchmore polymorphic than 𝛼3 domain
[85, 86]. This could account for the broader specificity of
LILR receptors in comparison with KIR2DL4 that binds
specifically HLA-G and no other HLA-I molecules. Also,
structural studies suggest that KIR2DL4 cannot bind HLA-
G dimers due to steric reasons [22].
The expression of LILRB1, LILRB2, and KIR2DL4 can be
induced by HLA-G without any costimulatory requirement,
which indicates that it can occur independently from any
immune response [87].
Besides these receptors, HLA-G can also bind to CD8
without TCR interaction, provoking NK cells and activated
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Figure 2: HLA-G isoforms and conformations. Membrane and soluble HLA-G isoforms are reported as monomeric and dimeric
conformation Zilberman, Eur J Immunol 2012 [23].
CD8+ T cells apoptosis, and FasL upregulation and secretion
[88]. Another putative HLA-G receptor is CD160. Interaction
of HLA-G with CD160 expressed by endothelial cells induces
the apoptosis of these cells [89] and inhibits cell proliferation,
migration, and tubule formation [90], inhibiting the angio-
genic process.
5. Posttranslational Modifications
of HLA-G Molecule
Although most studies are related to 𝛽2-m bound HLA-
G molecules that correspond to the originally described
structure, several results have demonstrated the existence of
modified variants of this structure. For example, expression
of 𝛽2-m free HLA-G, which can be originated by dissociation
of HLA-G complete isoforms [45], has been demonstrated in
different tissues such as placenta [78] or pancreatic endocrine
cells [91].
Besides Cys residues in 𝛼2 and 𝛼3 domains that allow
intramolecular disulphide bonds, HLA-G molecule presents
other important Cys residues. Cys42 in 𝛼1 domain and
Cys147 in 𝛼2 domain can form intermolecular disulphide
bonds giving rise to HLA-G dimers that can be observed
by SDS/PAGE under nonreducing conditions [92]. These
structures have been observed for all HLA-G isoforms except
HLA-G3 [93]. It has been estimated that about 40%ofHLA-G
molecules at trophoblastic cells surface are in a dimeric form;
meanwhile, only a small fraction of soluble HLA-G would
be constituted by HLA-G dimers [94]. Even more, villous
cytotrophoblast cells can produce dimers of 𝛽2-m free HLA-
G5 molecules [95].
Immunoblot analysis with 4H84 antibody rends bands of
diverse molecular weights (35–50 kDa) due to a glycosylation
of HLA-G through an Asn residue (Asn86). This modifi-
cation has been observed for both soluble and membrane
bound HLA-G [96]. Another posttranslational modification
observed in HLA-G is nitration in Tyr residues. Presence of
3-nitrotryrosine in HLA-G has been demonstrated in vivo
in biological fluids both in monomeric and multimeric form
[42] and in vitro after treatment with NO donors, which
also increase HLA-G shedding by metalloproteases [43]. The
detection of this modified HLA-G may characterize HLA-
G synthesized at sites of inflammation where there is an
important peroxide production.
Recently, HLA-G of molecular weights (70–76 kDa)
higher than those expected were observed in biological
fluids even when SDS/PAGE prior to western blot was
performed under reducing conditions [64]. These molecules
were associated with 𝛽2-m and could form dimers through
disulphide bonds. The importance of these structures resides
in the fact that they are not equivalently recognized by anti-
HLA-G antibodies and can originate discrepancies in HLA-
G quantification results.Thesemolecules were later identified
as ubiquitinated HLA-G molecules [97] with an intracellular
origin demonstrated by their presence in exosomes,which are
microvesicles of 50–100 nm originated from the endolysoso-
mal pathway and secreted by many different cell types [98].
These particles carries mRNA, miRNA, and proteins,
such as classical HLA-I molecules [98], and can exert distant
immune functions [98]. Exosomes could act as a mechanism
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to spread HLA-G tolerogenic functions because HLA-G
presence has been demonstrated in exosomes produced by
melanoma cells [99] and by early and term placenta [100].
Furthermore, in serum from pregnant womenHLA-G can be
detected incorporated into exosomes [101].
6. Analytical Challenging in
Soluble HLA-G Analysis
Searching in PubMed with the words HLA-G and ELISA
there are 175 papers published until November, 2013, mea-
suring soluble HLA-G in different biological fluids, including
serum, plasma, and exudates. From these papers, it is clear
that the measurement of soluble HLA-G is a potential
biomarker for diagnostic and/or prognostic in some phys-
iopathological situations, such as obstetric complications or
cancer [102]. In addition detectable levels of soluble HLA-
G in medium from embryo culture are associated with
success in vitro fertilization. For this reason, the disposal of
a good and widely accepted method to measure the soluble
HLA-G levels is of crucial importance to achieve a good
translation of results between different laboratories. Most are
in-house ELISA assays (Table 1) using as capture antibody the
mAb MEM-G/9, which has been raised against recombinant
human HLA-G refolded with 𝛽2-m and peptide [56]. Other
ELISAs are designed to measure exclusively HLA-G5 and/or
-G6 using anti-pan HLA-I antibody W6/32 as detection
antibody and the antibody 5A6G7 as capture antibody [103],
that reacts with the intron 4, which is exclusive of these two
isoforms [104]. As detection antibodymost assays use an anti-
𝛽2-m antibody or W6/32. These assays perform very well in
vitro using cell cultures, but the procedure for HLA-G mea-
surement is far from being resolved in vivo, and it has been a
source of conflicting results and interesting discussions [105–
108]. More than 15 years have passed since first reports of
a method for measuring HLA-G [55] and meanwhile some
important efforts have been carried out by several authors to
validate a method and a standard to measure soluble HLA-
G [58]. However, four main problems remain to be solved:
the identification of the main circulating HLA-G molecules
in vivo, the obtaining of a purified standard widely available,
the selection of the antibodies used in the procedure, and the
sensitivity of the methodology.
Probably the most important issue is related to the types
of HLA-Gmolecules present in biological fluids, as we do not
know yet the predominant isoform and whether it circulates
free or included in microvesicles, that is, exosomes [64], or
if they are mainly free molecules or associated with 𝛽2-m, or
even the influence ofmodifications such as dimerization [92],
nitration [42], or ubiquitination [97]. The presence of these
altered structures could be more relevant in cancer where
there is a deeply altered microenvironment. Probably, the
predominant structures in biological fluids are the dimeric
or multimeric forms, considering that the extracellular redox
status is more oxidized than the redox status and that there
is a low proportion of free SH groups from the Cys in
circulation [41]. It is not known if these proteins react equally
with different antibodies employed to measure HLA-G in
ELISA. Assuming the statement that only shed HLA-G1 and
HLA-G5 are released to circulation, we and others have
calculated the amount of sHLA-G1 by the difference between
the concentrations of sHLA-G1/HLA-G5 (usingMEM-G/9 as
capture mAb) and HLA-G5 (using 5A6G7 as capture mAb)
[109]. However, under the new vision of circulating HLA-
G molecules we cannot be sure now that this always occurs
in vivo. Unexpected results probably due to anomalous
structures were already documented in the Wet-Workshop
for Quantification of Soluble HLA-G held in 2004 [58]. In
this workshop it was observed in some samples that there
were HLA-G 5A6G7-immunoreactive molecules that were
not recognized by MEM-G/9.These different structures were
later elucidated to be new high molecular weight HLA-G
complexes [64].
A second important problem is the lack of a widely
available purified HLA-G molecule that could serve as a
standard. The only commercial soluble HLA-G available
kit nowadays for quantitative measurement (EXBIO Praha,
Czech Republic) uses a sHLA-G standard calibrator in terms
of arbitrary units/mL, but its equivalence to a protein con-
centration or biological activity is unknown. A high useful
method to produce a protein is by plasmid transfection
in bacteria, and both HLA-G1 and a fusion protein have
been produced by this methodology [110]. As synthetized
in a prokaryotic model, there are not the posttranslational
modifications produced in eukaryotes, mainly glycosylation
[96], and probably their conformation is not equivalent to
the native protein. For example, the fusion proteins produce
inhibition in NK cells only at levels much higher than the
native protein. HLA-G5 molecules purified from detergent
lysates of SF9 cells transfected with HLA-G5 and human
𝛽2-m have been used as a standard [58], while others have
purified the protein from HLA-G transfected cell culture
supernatants by affinity chromatography [111]. Also, other
studies use dilutions of tested cell supernatants as standard,
but the concentrations obtained cannot be extrapolated to
other studies [109]. A standard widely available that could
serve for data comparison between different laboratories
could be of interest, so data could be transferred between
papers. Until this standard becomes available, HLA-G level
comparisons between different laboratories should be taken
with caution. Same precautions should be taken when trans-
ferring the reference values that depend on not only both the
standard and methodology used, but also on the population
studied.
The third issue is related to the capability of the antibodies
to recognize all forms of HLA-G. Most of the anti-HLA-G
antibodies used in the ELISA recognize the native protein, are
very specific, and do not react with other HLA-I molecules
(Table 1) as it has been discussed elsewhere [112]. We do
not know yet if the reaction is equimolar with all HLA-G
molecules, and probably some proteins could be underrecog-
nized. For example, it was recently shown by flow cytometry
that MEM-G/9 can also react with HLA-G3, but the intensity
of the signal is weaker than with HLA-G1 [113]. Some HLA-
G complexes are underrecognized by MEM-G/9 and react
better with the anti-HLA-G antibodyG-233 [64]. In addition,
although HLA-G polymorphism is quite low with only 16
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Table 1: Examples of methods developed for measuring soluble HLA-G.
Type Standard Capture antibody Detectionantibody Detection Detection limit Reference
ELISA-
sandwich
HLA-G1/LCL
722.221 transfected
cells
W6.32 after
depletion with
TP25.99
anti-𝛽2-m Colorimetric 2.1 ng/mL [55]
ELISA-
sandwich None
87G, BFL.1 or
MEM-G/9 W6/32 Colorimetric O.D. [56]
ELISA-
sandwich
HLA-G transfected
CHO cells G233 56B Colorimetric 1 ng/mL [57]
ELISA-
sandwich
HLA-G5 protein
derived from insect
SF9 cells
MEM-G/9 anti-𝛽2-m Colorimetric 5 ng/mL [58]
ELISA-
sandwich
HLA-G5 protein
derived from insect
SF9 cells
5A6G7 W6/32 Colorimetric 5 ng/mL [58]
Luminex
HLA-G5 and beta2
m transfected SF9
cells
MEM-G9 anti-𝛽2-m Fluorescence 0.3 ng/mL [59]
ELISA-
sandwich
HLA-G transfected
LCL 721.221 cells MEM-G/9 W6/32 Fluorescence 1 ng/mL [60]
Bio-Plex
HLA-G5
transfected HeLa
cells
MEM-G/9 W6/32 Fluorescence 0.3 ng/mL [61]
ELISA-
sandwich
HLA-G transfected
LCL 721.221 cells MEM-G/9 W6/32 Chemiluminescence 2 ng/mL [62]
ELISA-
sandwich Purified HLA-G
HGY
(noncommercial)
Polyclonal
anti-HLA-G Colorimetric 1 U/mL [63]
ELISA-
sandwich
HLA-G1
transfected
LCL-721.221 cells
G233 anti-𝛽2-m Colorimetric 4 ng/mL [64]
proteins described to date, we do not know yet how they
affect the binding to the antibodies. Of particular interest
is that although the capture antibody in ELISA is HLA-G
specific, only a few authors have used a specific antibody for
HLA-G as detection antibody [63]. Instead, as we mentioned
before, the detection antibody used in most of the ELISAs is
an anti-𝛽2-m antibody. The fact that HLA-G1 and -G5 from
cell cultures are complexed with 𝛽2-m does not imply that
the same occurs always in vivo in all clinical situations. Some
of HLA-G released by the embryo is not bound to 𝛽2-m
[95], so these molecules would not be detected in this type
of assays. Although some authors have used the anti-HLA-G
mAb 4H84 in ELISA [114], its use is not recommended as it
can produce some nonspecific reactions with classical HLA-I
molecules, under certain methodological conditions [113].
Finally, another problem to be solved is the sensitivity of
the method. An important issue is that neither the functional
sensitivity nor the analytical sensitivity is usually reported.
Mostmethods are sandwich-ELISAs with colorimetric detec-
tion, whose reported detection limit is in the order of 1–
10 ng/mL and soluble HLA-G levels are below this detection
limit in many occasions. Thus, it is not known if there is no
circulatingHLA-G or if the procedure is not sensitive enough
for quantification of low HLA-G levels. Some authors have
improved the methodology, using fluorescence detection or
with procedures based on microspheres technology. The
detection limit decreased one order of magnitude compared
to the colorimetric based ELISA methodology [59, 61]. This
last methodology seems more appropriate for measuring
HLA-G in media from embryo culture during in vitro
fertilization [59].
7. Conclusions
HLA-G is a molecule that has been deeply studied during
the last two decades where the almost exclusive expression
in placenta has been well documented. When the HLA-G
gene is expressed, it can produce seven isoforms that exert
immune-suppressive functions by binding to its receptors.
However, there are some important basic concepts in its bio-
chemistry that remain not well explained yet. Among them,
the knowledge of the regulation of the protein expression
is a corner stone to understand how it can be expressed
ectopically in different pathological situations. This could
help to induce HLA-G in a tissue when a suppressive action
is convenient (e.g., organ transplantation) or to suppress it
when its expression is harmful (e.g., tumor). Also, along
recent yearsmultipleHLA-Gproteinmodifications have been
described, such as HLA-G dimers that bind LILRB receptors
with an affinity even higher than monomers, or nitration.
Journal of Immunology Research 7
Moreover, high molecular weight molecules of HLA-G have
been described as HLA-G complexed with ubiquitin. Fur-
thermore, circulating HLA-G has also been observed as
included in exosomes. The complete identification of these
circulating HLA-G structures would improve not only the
knowledge of this molecule but also the design of better
methods for analysis. These are important questions that
should be elucidated in order to understand the biology of
HLA-G and to clarify some discrepant results.
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